Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China
To analyze the coverage rate of adult herpes zoster (HZ) vaccine and the incidence of Adverse event following immunization (AEFI) in Jiangsu province, China. The vaccination information of HZ vaccine in people aged 50 years and above in Jiangsu province in 2023 and the AEFI information of HZ vaccine...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2449714 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594220214386688 |
|---|---|
| author | Xiang Sun Lei Zhang Tingting Zhang Jinning Sun Yan Xu Li Liu Yuan Bao Liu Ran Hu YaLi Fu Zhiguo Wang Hui Sun |
| author_facet | Xiang Sun Lei Zhang Tingting Zhang Jinning Sun Yan Xu Li Liu Yuan Bao Liu Ran Hu YaLi Fu Zhiguo Wang Hui Sun |
| author_sort | Xiang Sun |
| collection | DOAJ |
| description | To analyze the coverage rate of adult herpes zoster (HZ) vaccine and the incidence of Adverse event following immunization (AEFI) in Jiangsu province, China. The vaccination information of HZ vaccine in people aged 50 years and above in Jiangsu province in 2023 and the AEFI information of HZ vaccine from 2020 to 2023 were collected through the Jiangsu Province vaccination management information system and China AEFI information management system, and the vaccination rate and AEFI incidence of HZ vaccine were analyzed. The overall vaccination rate among individuals aged 50 years and above was merely 0.19%. About 20% of vaccinated individuals (12,821 people) received only the first dose, failing to complete the recommended two-dose regimen. A total of 43 and 217 cases of AEFIs following vaccination were reported after administration of the HZ vaccine during the periods of 2020–2021 and 2022–2023, respectively, resulting in reporting rates (RRs) of 240.7 and 201.2 per 100,000 doses, correspondingly. The majority of AEFIs following vaccination with HZ vaccines were common reactions, while rare reactions and coincidental events accounted for only 1.5% and 0.4% of cases, respectively. Over 55% of AEFIs occurred within 30 minutes post-vaccination , with fever, allergic eruptions, and drowsiness being the most reported systemic symptoms, and redness and induration being the main symptoms at the injection site. Despite the proven safety profile of the HZ vaccine, its coverage remains significantly low among individuals aged 50 years and above in Jiangsu Province, China as of 2023. The majority of AEFIs were mild and commonly observed. To enhance the comprehensiveness of post-marketing safety data, it is imperative to conduct further active surveillance studies. |
| format | Article |
| id | doaj-art-803c89e6c82e4c94aaa0c55d205e7aa9 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-803c89e6c82e4c94aaa0c55d205e7aa92025-01-19T23:57:39ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2449714Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, ChinaXiang Sun0Lei Zhang1Tingting Zhang2Jinning Sun3Yan Xu4Li Liu5Yuan Bao Liu6Ran Hu7YaLi Fu8Zhiguo Wang9Hui Sun10Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaMedical Record Office, Children’s Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Expanded Program on Immunization, Nanjing Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Epidemiological Research, Jiangsu Health Development Research Center, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaMedical Department, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, ChinaTo analyze the coverage rate of adult herpes zoster (HZ) vaccine and the incidence of Adverse event following immunization (AEFI) in Jiangsu province, China. The vaccination information of HZ vaccine in people aged 50 years and above in Jiangsu province in 2023 and the AEFI information of HZ vaccine from 2020 to 2023 were collected through the Jiangsu Province vaccination management information system and China AEFI information management system, and the vaccination rate and AEFI incidence of HZ vaccine were analyzed. The overall vaccination rate among individuals aged 50 years and above was merely 0.19%. About 20% of vaccinated individuals (12,821 people) received only the first dose, failing to complete the recommended two-dose regimen. A total of 43 and 217 cases of AEFIs following vaccination were reported after administration of the HZ vaccine during the periods of 2020–2021 and 2022–2023, respectively, resulting in reporting rates (RRs) of 240.7 and 201.2 per 100,000 doses, correspondingly. The majority of AEFIs following vaccination with HZ vaccines were common reactions, while rare reactions and coincidental events accounted for only 1.5% and 0.4% of cases, respectively. Over 55% of AEFIs occurred within 30 minutes post-vaccination , with fever, allergic eruptions, and drowsiness being the most reported systemic symptoms, and redness and induration being the main symptoms at the injection site. Despite the proven safety profile of the HZ vaccine, its coverage remains significantly low among individuals aged 50 years and above in Jiangsu Province, China as of 2023. The majority of AEFIs were mild and commonly observed. To enhance the comprehensiveness of post-marketing safety data, it is imperative to conduct further active surveillance studies.https://www.tandfonline.com/doi/10.1080/21645515.2025.2449714Herpes zoster vaccineadverse reactionsafetypost-marketing surveillance |
| spellingShingle | Xiang Sun Lei Zhang Tingting Zhang Jinning Sun Yan Xu Li Liu Yuan Bao Liu Ran Hu YaLi Fu Zhiguo Wang Hui Sun Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China Human Vaccines & Immunotherapeutics Herpes zoster vaccine adverse reaction safety post-marketing surveillance |
| title | Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China |
| title_full | Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China |
| title_fullStr | Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China |
| title_full_unstemmed | Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China |
| title_short | Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China |
| title_sort | surveillance on the coverage of herpes zoster vaccine and post marketing adverse events in jiangsu province china |
| topic | Herpes zoster vaccine adverse reaction safety post-marketing surveillance |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2449714 |
| work_keys_str_mv | AT xiangsun surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT leizhang surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT tingtingzhang surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT jinningsun surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT yanxu surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT liliu surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT yuanbaoliu surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT ranhu surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT yalifu surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT zhiguowang surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina AT huisun surveillanceonthecoverageofherpeszostervaccineandpostmarketingadverseeventsinjiangsuprovincechina |